IMA
ImageneBio Inc
Biotechnology
Market Cap$61M
5Y Perf.-98.4%
Build Your Comparison
Side-by-side financial analysisIMA
SRZN
Try popular comparisons:
Stock Comparison
IMA vs SRZN
Revenue, margins, valuation, and 5-year total return — side by side.
SRZN
Surrozen, Inc.
Biotechnology
Market Cap$175M
5Y Perf.-83.8%
IMA vs SRZN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  IMA |  SRZN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $61M | $175M |
| Revenue (TTM) | $0.00 | $7M |
| Net Income (TTM) | $-45M | $-343M |
| Gross Margin | -29.1% | 99.1% |
| Operating Margin | -60.6% | -5.7% |
| Total Debt | $10M | $7M |
| Cash & Equiv. | $35M | $89M |
IMA vs SRZN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMA
SRZN
| Stock | Mar 21 | Jun 26 | Return |
|---|---|---|---|
| ImageneBio Inc (IMA) | 100 | 1.6 | -98.4% |
| Surrozen, Inc. (SRZN) | 100 | 16.2 | -83.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMA vs SRZN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: SRZN leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ImageneBio Inc is the stronger pick specifically for capital preservation and lower volatility and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
🥇SRZN emerged as the overall leader. Track its performance:
IMA
ImageneBio Inc
The Income Pick
IMA is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.83
- Lower volatility, beta 0.83, Low D/E 7.5%, current ratio 12.49x
- Beta 0.83, current ratio 12.49x
Best for: income & stability and sleep-well-at-night
SRZN
Surrozen, Inc.
The Growth Play
SRZN carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -67.4%, EPS growth -49.4%, 3Y rev CAGR -34.7%
- -84.6% 10Y total return vs IMA's -98.6%
- -67.4% revenue growth vs IMA's -77.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  SRZN | -67.4% revenue growth vs IMA's -77.1% |
| Quality / Margins | SRZN | -45.7% margin vs IMA's -56.7% |
| Stability / Safety |  IMA | Beta 0.83 vs SRZN's 1.25 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | SRZN | +148.8% vs IMA's -67.0% |
| Efficiency (ROA) | IMA | -31.3% ROA vs SRZN's -329.2% |
IMA vs SRZN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
IMA vs SRZN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLSRZNLAGGINGIMA
IMAImageneBio Inc
0leads
SRZNSurrozen, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs IMAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
SRZN5/5
Valuation MetricsMultiples, price ratios, and targets
SRZN2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
SRZN3/5
Total Returns1Y, 3Y, 5Y total returns with dividends
SRZN6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
SRZN leads this category, winning 5 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
SRZN and IMA operate at a comparable scale, with $7M and $0 in trailing revenue. SRZN is the more profitable business, keeping -45.7% of every revenue dollar as net income compared to IMA's -56.7%.
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $7M |
| EBITDAEarnings before interest/tax | -$53M | -$43M |
| Net IncomeAfter-tax profit | -$45M | -$343M |
| Free Cash FlowCash after capex | -$52M | -$34M |
| Gross MarginGross profit ÷ Revenue | -29.1% | +99.1% |
| Operating MarginEBIT ÷ Revenue | -60.6% | -5.7% |
| Net MarginNet income ÷ Revenue | -56.7% | -45.7% |
| FCF MarginFCF ÷ Revenue | -59.8% | -4.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +4.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -4.3% | -56.8% |
SRZN leads this category, winning 5 of 5 comparable metrics.
Valuation Metrics
SRZN leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| Market CapShares × price | $61M | $175M |
| Enterprise ValueMkt cap + debt − cash | $36M | $92M |
| Trailing P/EPrice ÷ TTM EPS | -0.50x | -0.72x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 76.54x | 50.30x |
| Price / BookPrice ÷ Book value/share | 0.20x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
SRZN leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
SRZN leads this category, winning 3 of 5 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), SRZN scores 3/9 vs IMA's 2/9, reflecting mixed financial health.
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -35.2% | — |
| ROA (TTM)Return on assets | -31.3% | -3.3% |
| ROICReturn on invested capital | -35.9% | — |
| ROCEReturn on capital employed | -35.6% | -64.8% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 |
| Debt / EquityFinancial leverage | 0.08x | — |
| Net DebtTotal debt minus cash | -$25M | -$83M |
| Cash & Equiv.Liquid assets | $35M | $89M |
| Total DebtShort + long-term debt | $10M | $7M |
| Interest CoverageEBIT ÷ Interest expense | -560.22x | — |
SRZN leads this category, winning 3 of 5 comparable metrics.
Total Returns (Dividends Reinvested)
SRZN leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in SRZN five years ago would be worth $1,575 today (with dividends reinvested), compared to $330 for IMA. Over the past 12 months, SRZN leads with a +148.8% total return vs IMA's -67.0%. The 3-year compound annual growth rate (CAGR) favors SRZN at 35.6% vs IMA's -59.4% — a key indicator of consistent wealth creation.
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -19.7% | +8.5% |
| 1-Year ReturnPast 12 months | -67.0% | +148.8% |
| 3-Year ReturnCumulative with dividends | -93.3% | +149.5% |
| 5-Year ReturnCumulative with dividends | -96.7% | -84.2% |
| 10-Year ReturnCumulative with dividends | -98.6% | -84.6% |
| CAGR (3Y)Annualised 3-year return | -59.4% | +35.6% |
SRZN leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMA and SRZN each lead in 1 of 2 comparable metrics.
Risk & Volatility
IMA is the less volatile stock with a 0.83 beta — it tends to amplify market swings less than SRZN's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SRZN currently trades 66.8% from its 52-week high vs IMA's 30.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.83x | 1.25x |
| 52-Week HighHighest price in past year | $18.00 | $35.00 |
| 52-Week LowLowest price in past year | $1.36 | $8.00 |
| % of 52W HighCurrent price vs 52-week peak | +30.2% | +66.8% |
| RSI (14)Momentum oscillator 0–100 | 51.8 | 41.7 |
| Avg Volume (50D)Average daily shares traded | 432K | 111K |
Evenly matched — IMA and SRZN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | IMAImageneBio Inc | SRZNSurrozen, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $42.00 |
| # AnalystsCovering analysts | — | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
SRZN leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallSurrozen, Inc. (SRZN)Leads 4 of 6 categories
Loading custom metrics...
IMA vs SRZN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMA or SRZN a better buy right now?
For growth investors, Surrozen, Inc.
(SRZN) is the stronger pick with -67. 4% revenue growth year-over-year, versus -77. 1% for ImageneBio Inc (IMA). Analysts rate Surrozen, Inc. (SRZN) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMA or SRZN?
Over the past 5 years, Surrozen, Inc.
(SRZN) delivered a total return of -84. 2%, compared to -96. 7% for ImageneBio Inc (IMA). Over 10 years, the gap is even starker: SRZN returned -84. 6% versus IMA's -98. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMA or SRZN?
By beta (market sensitivity over 5 years), ImageneBio Inc (IMA) is the lower-risk stock at 0.
83β versus Surrozen, Inc. 's 1. 25β — meaning SRZN is approximately 50% more volatile than IMA relative to the S&P 500.
04Which is growing faster — IMA or SRZN?
By revenue growth (latest reported year), Surrozen, Inc.
(SRZN) is pulling ahead at -67. 4% versus -77. 1% for ImageneBio Inc (IMA). On earnings-per-share growth, the picture is similar: Surrozen, Inc. grew EPS -49. 4% year-over-year, compared to -954. 9% for ImageneBio Inc. Over a 3-year CAGR, SRZN leads at -34. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMA or SRZN?
ImageneBio Inc (IMA) is the more profitable company, earning -56.
7% net margin versus -69. 6% for Surrozen, Inc. — meaning it keeps -56. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SRZN leads at -1210. 6% versus -60. 6% for IMA. At the gross margin level — before operating expenses — SRZN leads at 84. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IMA or SRZN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IMA or SRZN better for a retirement portfolio?
For long-horizon retirement investors, ImageneBio Inc (IMA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
83)). Both have compounded well over 10 years (IMA: -98. 6%, SRZN: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMA and SRZN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.